NURLF (Neural Therapeutics) Change In Working Capital: $0.05 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Change In Working Capital?

Neural Therapeutics NURLF Change In Working Capital is $0.05 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's change in working capital for the quarter that ended in Jan. 2026 was $0.05 Mil.

Neural Therapeutics's change in working capital for the fiscal year that ended in Jul. 2025 was $0.13 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Neural Therapeutics Change In Working Capital Related Terms

Neural Therapeutics Change In Working Capital Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Change In Working Capital Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Change In Working Capital
Get a 7-Day Free Trial 0.22 0.11 0.42 0.22 0.13

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.02 -0.03 0.02 0.05

Neural Therapeutics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Working Capital of $0.05 Mil mean?
Neural Therapeutics (NURLF) has a Change In Working Capital of $0.05 Mil as of Jan. 2026. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Neural Therapeutics.
Is Neural Therapeutics' Change In Working Capital too high?
Neural Therapeutics' current Change In Working Capital is $0.05 Mil.
How does Neural Therapeutics' Change In Working Capital compare to VRTX and REGN?
Neural Therapeutics' Change In Working Capital of $0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Working Capital for a Biotechnology company?
A good Change In Working Capital depends on the Biotechnology industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Working Capital mean?
A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Neural Therapeutics. Neural Therapeutics's current Change In Working Capital is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current Change In Working Capital of $0.05 Mil. The current Change In Working Capital is $0.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Working Capital calculated?
Change In Working Capital is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current Change In Working Capital is $0.05 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:GermanyNURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.